science at Stanford University and the Lucile Packard Children’s Hospital. Dr. Butte trained in computer science at Brown University, worked as a software engineer at Apple and Microsoft, received an M.D. at Brown University, trained in pediatrics and pediatric endocrinology at Children’s Hospital Boston, and then received a Ph.D. in health sciences and technology from Harvard Medical School and the Massachusetts Institute of Technology. Dr. Butte is also a founder of Personalis, which provides clinical interpretations of whole-genome sequences, and NuMedii, which finds new uses for drugs. The Butte laboratory builds and applies tools that convert more than 300 billion points of molecular, clinical, and epidemiological data that have been measured by researchers and clinicians over the past decade into diagnostics, therapeutics, and new insights into disease. To facilitate this method, the Butte laboratory has developed tools to automatically index and find genomic datasets based on the phenotypic and contextual details of each experiment to deconvolve multi-cellular samples, and to perform these calculations on the Internet cloud. Dr. Butte has authored more than 120 publications and delivered more than 140 invited presentations in personalized and systems medicine, biomedical informatics, and molecular diabetes, including 30 at the National Academy of Sciences, Institute of Medicine, National Institutes of Health (NIH), or NIH-related meetings. Dr. Butte’s research has been featured in the New York Times and the International Herald Tribune (2008), the Wall Street Journal (2010 to 2012), and the San Jose Mercury News (2010). Dr. Butte has received several awards, including the 2012 FierceBiotech IT “Top 10 Biotech Techies” award and the 2011 National Human Genome Research Institute Genomic Advance of the Month.
Geoffrey Duyk, M.D., Ph.D., is a partner and managing director of TPG Biotechnology. Prior to joining TPG Biotechnology in 2004, Dr. Duyk served on the board of directors and was president of research and development at Exelixis, Inc., where he led a group of more than 550 people focused on the discovery and development of small-molecule therapeutics. Prior to his work at Exelixis, Inc., he was one of the founding scientific staff at Millennium Pharmaceuticals, Inc. As vice president of Genomics at Millennium Pharmaceuticals, Inc., Dr. Duyk was responsible for building and leading the informatics, automation, DNA sequencing, and genotyping groups as well as the mouse and human genetics group. Prior to this, Dr. Duyk was an assistant professor at Harvard Medical School in the department of genetics and assistant investigator of the Howard Hughes Medical Institute. While at Harvard Medical School, Dr. Duyk was a co–principal investigator in the National Institutes of Health (NIH)-funded Cooperative Human Linkage Center. Dr. Duyk has been and continues to be a member of numerous NIH panels and oversight committees focused